ACM
KYMR icon

Aster Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Aster Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06K Buy
+112
New +$8.87K ﹤0.01% 729
2025
Q3 		– Sell
-5,661
Closed -$247K – 1185
2025
Q2 		$247K Buy
5,661
+3,945
+230% +$136K 0.06% 333
2025
Q1 		$53.8K Buy
1,716
+1,629
+1,872% +$59.4K 0.01% 803
2024
Q4 		$3.5K Buy
+87
New +$3.93K ﹤0.01% 905

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Aster Capital Management's KYMR Position: Q1 2026 in Review

Aster Capital Management opened a new position in Kymera Therapeutics (KYMR) in Q1 2026: 112 shares worth $3.06K. The stake represents ﹤0.01% of the portfolio and ranks #729 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in KYMR as recently as Q2 2025.

Aster Capital Management first reported a position in KYMR in Q4 2024 and has held it in 4 quarters since. The position peaked at $247K in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Aster Capital Management held 112 shares of Kymera Therapeutics worth $3.06K as of Q1 2026.
  • Kymera Therapeutics was a new Aster Capital Management position in Q1 2026.
  • Kymera Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #729 holding.
  • Aster Capital Management first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Kymera Therapeutics position peaked at $247K in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.